{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:41:21Z","timestamp":1791945681068,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.genhosppsych.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T16:20:03Z","timestamp":1725380403000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial"],"prefix":"10.1016","volume":"91","author":[{"given":"ShuJia","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiuXia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WanQiu","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/appi.ajp.20231022","article-title":"Late-life depression, antidepressant treatment, and cognition: the short haul and the long haul","volume":"181","author":"Steffens","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamapsychiatry.2022.0020","article-title":"Davatzikos C, iSTAGING consortium, ADNI, BIOCARD, and BLSA. Characterizing heterogeneity in neuroimaging, cognition, clinical symptoms, and genetics among patients with late-life depression","volume":"79","author":"Wen","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0015","series-title":"StatPearls","article-title":"Late-life depression","author":"Sekhon","year":"2024"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11920-012-0278-7","article-title":"Depression and cognitive impairment in older adults","volume":"14","author":"Weisenbach","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2019.05.013","article-title":"Cognitive dysfunction in major depression: from assessment to novel therapies","volume":"202","author":"Atique-Ur-Rehman","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"Suppl E1","key":"10.1016\/j.genhosppsych.2024.09.001_bb0030","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1176\/appi.ajp.20230919","article-title":"Optimizing the treatment of late-life depression","volume":"181","author":"Walaszek","year":"2024","journal-title":"AJP"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41398-022-02249-6","article-title":"Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research","volume":"12","author":"Colwell","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0045","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1017\/S1461145712001605","article-title":"Multi-modality: a new approach for the treatment of major depressive disorder","volume":"16","author":"Richelson","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0055","first-page":"37","article-title":"Cognitive outcomes are differentially associated with depression severity trajectories during psychotherapy treatment for late life major depressive disorder","author":"Kassel","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.06.034","article-title":"Treatment of neurocognitive symptoms in unipolar depression: a systematic review and future perspectives","volume":"221","author":"Salagre","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0065","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.4088\/JCP.10m06223blu","article-title":"The future of psychopharmacology of depression","volume":"71","author":"Chang","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12916-016-0560-3","article-title":"Cognitive remission: a novel objective for the treatment of major depression?","volume":"14","author":"Bortolato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(86)90325-6","article-title":"Buspirone: review of its pharmacology and current perspectives on its mechanism of action","volume":"80","author":"Eison","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0080","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.eurpsy.2008.01.456","article-title":"P0166 - effect of Buspirone, a serotonin partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"23","author":"Sumiyoshi","year":"2008","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2019.05.006","article-title":"Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia","volume":"209","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/nyas.12669","article-title":"Diagnosis and treatment of depression and cognitive impairment in late life","volume":"1345","author":"Morimoto","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jad.2024.02.030","article-title":"Individualized prediction of cognitive test scores from functional brain connectome in patients with first-episode late-life depression","volume":"352","author":"Liu","year":"2024","journal-title":"J Affect Disord"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(24)00139-9","article-title":"Recommendations for accurate reporting in medical research statistics","volume":"403","author":"Mansournia","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0115","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appelberg","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0120","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1460-9568.1992.tb00145.x","article-title":"The effect of Apomorphine and Buspirone on regional cerebral blood flow during the performance of a cognitive task\u2014measuring Neuromodulatory effects of psychotropic drugs in man","volume":"4","year":"1992","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0125","first-page":"65","article-title":"Effects of antidepressants on cognitive functions. Review of the literature","volume":"20","author":"Amado-Boccara","year":"1994","journal-title":"Encephale"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1176\/appi.ajp.20230392","article-title":"Cognitive outcomes after antidepressant pharmacotherapy for late-life depression: a systematic review and meta-analysis","volume":"181","author":"Ainsworth","year":"2024","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0140","first-page":"6","article-title":"The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory","author":"Stiedl","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-02249-6","article-title":"Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research","volume":"12","author":"Colwell","year":"2022","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23414","article-title":"Buspirone attenuated methotrexate-induced hippocampal toxicity in rats by regulating Nrf2\/HO-1, PPAR-\u03b3, NF-\u03baB\/nNOS, and ROS\/NLRP3\/caspase-1 signaling pathways","volume":"37","author":"Althagafy","year":"2023","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0306-4522(99)00211-0","article-title":"Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin receptors and blockade of \u03b1-adrenergic receptors underlie its actions1A2","volume":"93","author":"Gobert","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.euroneuro.2015.01.009","article-title":"The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing","volume":"25","author":"Bernasconi","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF02245127","article-title":"Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man","volume":"108","author":"Grasby","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0170","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1089\/neu.2012.2358","article-title":"Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist Buspirone","volume":"29","author":"Olsen","year":"2012","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1476-5381.1990.tb12961.x","article-title":"The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone","volume":"99","author":"Fletcher","year":"1990","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1017\/S1092852913000540","article-title":"Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction","volume":"19","author":"Pehrson","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0185","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/1520-6394(2000)12:1+<50::AID-DA6>3.0.CO;2-4","article-title":"Efficacy of venlafaxine in the treatment of severe depression","volume":"12","author":"Kienke","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0195","first-page":"450","article-title":"Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia","volume":"56","author":"Guelfi","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0200","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0006-3223(02)01425-7","article-title":"Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression","volume":"52","author":"Stahl","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0205","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis","volume":"180","author":"Smith","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/da.10045","article-title":"Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms","volume":"16","author":"Davidson","year":"2002","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0215","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.biopsych.2007.03.027","article-title":"Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents","volume":"62","author":"Papakostas","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00406-009-0003-7","article-title":"Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity","volume":"259","author":"Schmitt","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0225","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/da.22964","article-title":"Comorbid anxiety in late-life depression: relationship with remission and suicidal ideation on venlafaxine treatment","volume":"36","author":"Saade","year":"2019","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/1520-6394(2000)12:1+<77::AID-DA10>3.0.CO;2-1","article-title":"Efficacy of venlafaxine in mixed depression-anxiety states","volume":"12","author":"Gorman","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/bjp.175.1.12","article-title":"Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison","volume":"175","author":"Poirier","year":"1999","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.genhosppsych.2024.09.001_bb0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/1520-6394(2000)12:1+<55::AID-DA7>3.0.CO;2-X","article-title":"Venlafaxine and treatment-resistant depression","volume":"12","author":"Thase","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0245","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure","volume":"59","author":"Thase","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.09.001_bb0250","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/gps.1190","article-title":"Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram","volume":"19","author":"Allard","year":"2004","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324001841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324001841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T09:22:03Z","timestamp":1733736123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834324001841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"alternative-id":["S0163834324001841"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.09.001","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the efficacy and safety of combined buspirone and venlafaxine treatment in late-life depression accompanied by cognitive impairment: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}